The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1521
Oxymetazoline Cream (Rhofade) for Rosacea
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the selective alpha1A-adrenergic receptor agonist oxymetazoline as a 1% cream (Rhofade – Allergan) for topical treatment of persistent facial erythema of rosacea in adults. Brimonidine, a selective alpha2-adrenergic receptor agonist, was approved in 2013 as a 0.33% gel (Mirvaso) for the same indication.1 Like Mirvaso, Rhofade is not indicated for treatment of inflammatory lesions of rosacea. Oxymetazoline has been available over the counter for many years as a nasal decongestant spray (Afrin, and others).

TREATMENT OF ROSACEA — Rosacea is a common, chronic inflammatory facial condition of unknown cause characterized by erythema, telangiectasia, and/or acneiform lesions (papules and pustules), usually on the central part of the face. Avoidance of exposure to extremes of temperature, hot baths ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Oxymetazoline Cream (Rhofade) for Rosacea
Article code: 1521c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian